ZYUS Life Sciences (TSE:ZYUS) has released an update.
ZYUS Life Sciences Corporation has secured a CAD$2 million unsecured loan from an independent director to support its ongoing clinical trial activities. This financial move underscores insider confidence in ZYUS’s mission to develop non-opioid therapies for pain management. The loan, which carries a 12% interest rate, highlights the company’s commitment to advancing its pharmaceutical endeavors.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.
